Skip to main content
. 2021 Jun 9;15(12):2022–2030. doi: 10.1093/ecco-jcc/jjab099

Figure 2.

Figure 2.

Improvements in abdominal pain with upadacitinib. A. Percentage of patients reporting an abdominal pain score of 0 from Weeks 2 to 8. B. Reduction in mean abdominal pain from Weeks 2 to 8. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared with placebo. Panel A is analysed NRI. Panel B is analysed LOCF ITT population. ITT, intent-to-treat; LOCF, last observation carried forward; NRI, non-responder imputation.